白细胞介素-32在肺鳞癌和肺腺癌中的表达及其与预后的相关性分析

Expression of interleukin-32 in lung squamous cell carcinoma and lung adenocarcinoma and its correlation with prognosis

目的探讨IL-32在肺腺癌和肺鳞癌中的表达及其与预后的相关性。方法收集2017年6月—2018年6月于河南省胸科医院就诊并住院治疗的86例非小细胞肺癌(non-small cell lung cancer,NSCLC)患者癌组织及癌旁组织样本,其中鳞癌50例,腺癌36例;采用免疫组织化学染色法检测IL-32表达情况。比较两组患者的IL-32阳性表达率和一般资料(包括年龄、性别、吸烟史、病理类型、肿瘤分化程度、TNM分期、最大肿瘤直径、有无淋巴结转移、治疗方案)。采用Kaplan-Meier曲线和单因素、多因素Cox回归分析NSCLC患者无进展生存期(progression free survival,PFS)和总生存期的影响因素。结果IL-32在NSCLC组织中的阳性表达率显著高于癌旁组织[48.8%(42/86)比18.6%(16/86),P<0.05]。肺鳞癌的IL-32阳性表达率显著低于肺腺癌[28.0%(14/50)比77.8%(28/36),P<0.001]。肺鳞癌中,IL-32阳性组吸烟患者占比显著低于IL-32阴性组(χ^(2)=6.822,P=0.009),IL-32阴性组与阳性组间PFS和总生存期的差异均无统计学意义(χ^(2)=1.506,P=0.220;χ^(2)=2.673,P=0.102),且IL-32阳性不是其预后影响因素。肺腺癌中,IL-32阳性组淋巴结转移率显著高于阴性组(χ^(2)=6.545,P=0.011),PFS和总生存期均短于IL-32阴性组(χ^(2)=6.277,P=0.012;χ^(2)=3.871,P=0.048),且IL-32阳性是肺腺癌患者PFS[风险比(HR)为11.027,95%CI为2.581~47.106,P=0.001]和总生存期(HR为6.997,95%CI为1.775~27.591,P=0.005)的独立影响因素。结论IL-32在肺腺癌组织中大部分呈阳性表达,且与预后生存期相关。

Objective To investigate the expression of Interleukin-32(IL-32)in lung adenocarcinoma and squamous cell carcinoma and its correlation with prognosis.Methods The samples of cancerous and paracancerous tissues from 86 patients with non-small cell lung cancer(NSCLC)in Henan Provincial Chest Hospital from June 2017 to June 2018 were collected.There were 50 patients with squamous cell carcinoma and 36 patients with adenocarcinoma.The expression of IL-32 was detected by immunohistochemistry.The IL-32 positive expression rate and general information(including age,sex composition,history of smoking,pathological type,degree of tumor differentiation,TNM stage,maximum tumor diameter,lymph node metastasis,and treatment plan)were investigated.Kaplan-Meier survival function and Cox regression were used to analyze the risk factors of progression free survival(PFS)and overall survival of NSCLC patients.Results The positive expression rate of IL-32 in NSCLC tissues was significantly higher than that in paracancerous tissues(48.8%[42/86])vs.18.6%[16/86],P<0.05).The positive expression rate of IL-32 in squamous cell carcinoma was significantly lower than that in adenocarcinoma((28%[14/50])vs.77.8%[28/36],P<0.001).In patients with squamous cell carcinoma,the proportion of smoking in IL-32 positive group was significantly lower than that in IL-32 negative group(χ^(2)=6.822,P=0.009),but there were no significant differences in PFS or overall survival between IL-32 negative group and positive group(χ^(2)=1.506,P=0.220;χ^(2)=2.673,P=0.102),and IL-32 was not a prognostic factor.In adenocarcinoma,the lymph node metastasis rate in IL-32 positive group was significantly higher than that in IL-32 negative group(χ^(2)=6.545,P=0.011),PFS and overall survival in IL-32 positive group were significantly higher than those in IL-32 negative group(χ^(2)=6.277,P=0.012;χ^(2)=3.871,P=0.048),and IL-32 was an independent factor for PFS(hazard ratio[HR]=11.027,95%CI:2.581-47.106,P=0.001)and overall survival(HR=6.997,95%CI:1.775-27.591,P=0.005).Conclusion The expression of IL-32 is positive in most lung adenocarcinoma tissues and is correlated with prognosis.